A new study, published by Frontiers in Space, reveals promising results from an experiment on the International Space Station (ISS) for treating and preventing post-traumatic osteoarthritis (PTOA). This condition affects roughly one-fifth of the 650 million people worldwide with osteoarthritis. Using a human tissue chip model on the International Space Station, the ISS researchers observed…
Q&A: USC researchers uncover potential osteoarthritis treatment breakthrough with R805/CX-011
Researchers at the Keck School of Medicine at the University of Southern California (USC) have discovered a drug compound, R805/CX-011, with the potential to alleviate the painful hyperinflammation from osteoarthritis. The findings concerning the prospective osteoarthritis treatment breakthrough, published in Science Translational Medicine, showed positive effects in animal models and could pave the way for…
Vericel’s unique biopharma focus: Tackling unmet needs in sports medicine and burn treatment
Vericel (Nasdaq:VCEL), a biopharma focused on sports medicine and severe burn care therapies, has a portfolio including the cartilage repair treatment MACI and the burn treatments Epicel and NexoBrid. Focal cartilage defects, which occur in approximately 60% of arthroscopies, can lead to debilitating osteoarthritis if left untreated. Vericel’s flagship product, MACI, tackles this medical challenge…
Why Medipost is upbeat about its stem cell-based treatment of osteoarthritis
Medipost has announced that its allogeneic human umbilical cord blood-derived mesenchymal stem cell product for knee osteoarthritis was featured in the peer-reviewed Orthopaedic Journal of Sports Medicine. The Seoul, Korea–headquartered company specializes in allogeneic umbilical cord blood-derived mesenchymal stem cells for various therapeutic applications. Medipost’s Phase 3 study found that 97% of recipients of its…